- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1000KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 430KB)
Palbociclib – March 2022
Palbociclib: Tablet 75 mg, Tablet 100 mg, Tablet 125 mg; Ibrance®
Last updated
1 July 2022